Clinical research firm Bio-Images Research has appointed a director of regulatory affairs.
Dr Sarah Connolly, who has been with the Glasgow-based company for the past four years, will take responsibility for GMP, regulatory and ethical approvals.
The appointment is designed to maintain the highest level of ethical and regulatory standards as the company's pipeline of clinical studies steadily increases.
Bio-Images has completed three clinical studies this year and claims to be in the forefront of a small field of providers of gamma scintigraphy imaging services, which allow multi-national pharma companies to outsource some of their clinical research.
Dr Connolly joined the company after completing her PhD in Pharmaceutical Sciences at the University of Strathclyde in 2007.
Bio-Images Research appoints director of regulatory affairs
To maintain highest level of ethical standards as firm expands
You may also like
Research & Development
Cirena and Epigenica launch technologies to accelerate genome editing and epigenomic research
Two life sciences companies have announced new technologies designed to address long-standing bottlenecks in genome editing and epigenomic analysis, offering faster timelines and improved reproducibility for researchers in academia and industry
Regulatory
NHS, MHRA and Medicines UK launch Project Revive to tackle medicine shortages
NHS England, the MHRA and Medicines UK have launched Project Revive, a collaborative pilot designed to address critical medicines shortages by fast-tracking dormant MHRA-approved licences and creating dedicated NHS purchasing arrangements to improve long-term supply resilience
Research & Development
AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic
The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies